Indicated for: cancer; post-transplant immunosuppression
Route of administration: oral
Substance: everolimus (immunosuppressant)
ATC: L01EG02 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Mammalian target of rapamycin (MTOR) kinase inhibitors)
Everolimus is a medication used in the treatment of certain types of cancer, as well as for preventing organ rejection after transplantation. It works by inhibiting a protein involved in cell growth and multiplication, thus helping to slow disease progression and reduce the risk of transplant rejection.
Everolimus is usually administered as tablets, according to the doctor's instructions, and the dose is adjusted depending on the condition being treated and the patient's response to therapy.
Side effects may include decreased immunity, infections, mouth ulcers, fatigue, digestive disorders, or increased blood sugar and cholesterol levels. In rare cases, severe reactions may occur, which is why careful monitoring is necessary during treatment.
Everolimus is an important option for patients with certain forms of cancer or who have undergone a transplant, helping to improve prognosis and increase the chances of treatment success.